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INTRODUCTION 
Primordial cells or stem cells are multipotent undi-
fferentiated cells with the capacity to proliferate and 
originate cells of any lineage, thereby forming any 
tissue in the organism.
Stem cells can be classified as embryonic stem 
cells, which are found in the internal cellular mass 
of the blastocyst (embryo), or as somatic or adult 
stem cells, which are found in tissues developed by 
the fetus or newborn, or in adults. The somatic type 
can be obtained from bone marrow, peripheral blood, 
umbilical cord, fetal liver, neural tissue or a variety 
of mesenchymal cells in adults, such the synovium, 
periosteum, muscle tissue or adipose tissue.
In the bone marrow, there are at least two popula-
tions of progenitor stem cells: hematopoietic progeni-
tor cells and mesenchymal progenitor cells(1).
Hematopoietic progenitor cells express a membra-
ne glycoprotein that makes it possible to identify and 
quantify such cells: the CD34 antigen. Other cells 
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stem cells. Bone marrow is one of the main locations for 
isolating primordial cells, and there are two lineages: hema-
topoietic and mesenchymal progenitor cells. There are seve-
ral uses for these undifferentiated cells in orthopedics, going 
that also express CD34 include endothelial cells, em-
bryonic fibroblasts and some cells within the fetal and 
adult nerve tissue. On the other hand, mesenchymal 
progenitor cells do not present any known cell surface 
marker. They can also be found in several solid organs 
and are identified solely through cell culturing. 
These two cell populations are present in bone mar-
row and, under normal conditions, only 0.1% of them 
circulate in the peripheral blood. This number may 
increase around 30 to 50-fold after administration of 
hematopoietic colony-stimulating factors, especially 
G-CSF (granulocyte colony-stimulating factor).
OBJECTIVES
The aim of this paper was to provide better un-
derstanding of the nature of stem cells and their im-
portance in medicine as a whole and in orthopedics 
especially, by covering the subject from its history to 
the current research.
With advances in medicine, it is now possible to 
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from cartilaginous lesions in osteoarthrosis, osteochondritis 
dissecans and patellar chondromalacia, to bone lesions like 
in pseudarthrosis or bone losses, or nerve lesions like in 
spinal cord trauma. Studying stem cells is probably the most 
promising field of study of all within medicine, and this is 
shortly going to revolutionize all medical specialties (both 
clinical and surgical) and thus provide solutions for diseases 
that today are difficult to deal with.
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extract, cultivate and reinfuse these progenitor cells 
for therapeutic purposes, to form various tissue types, 
including bone, liver, neural or adipose tissue(2). 
In orthopedics and traumatology, these cells can 
be used to form new tissues such as nerves, bone, 
cartilage and dense connective tissue (ligaments and 
tendons) (Figure 1).
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Figure 1 – Possible uses of multipotent cells for forming a variety 
of tissues.
Figure  2 – Magnetic resonance imaging on lumbar spine, with 
T1 weighting, showing spinal cord compression resulting from 
a fragment of a vertebral body that was displaced posteriorly.
spasticity and prescribe physiotherapy(4,5). However, 
research developed within this field has indicated that 
acute lesions of the spinal cord can be minimized 
through using drugs, provided that they are adminis-
tered shortly after the trauma(6-10).
At the start of this century, the first experiments 
on the physiopathology of spinal injuries were con-
ducted(11,12). However, these studies were only taken 
up again later on in the past decade, by investigators 
who started to place value on time-dependent changes 
within the pathology of spinal cord injuries(13,14).
The immense neurological deficits that result from 
spinal cord injuries come from the sum of two distinct 
events: the initial mechanical injury and the seconda-
ry endogenous lesion that is consequent to the initial 
injury(15-20). This primary injury is produced directly 
by the trauma, and involves cell death and release of 
electrolytes, metabolites and enzymes. It is therefo-
re a mechanical process that does not depend on cell 
control. Secondary lesions in the spinal cord involve 
complex biochemical changes that arise as a cascade 
of events comprising edema, inflammation, ischemia, 
reperfusion, growth factors, calcium metabolism and 
lipid peroxidase, and scientific investigative efforts 
have been concentrated on such events with the aim of 
controlling them(20-30). In pharmacological terms, drugs 
that modulate the endogenous response to primary 
injuries are being progressively introduced with the 
aim of limiting the tissue damage and improving the 
NERVE TISSUE
The use of totipotent cells to form nerve tissue has 
importance in relation to degenerative diseases like 
Parkinson and in spinal cord injuries. In this section, 
we deal with the latter (Figure 2).
The first report of difficulties in treating patients 
with spinal cord injuries dates from 3000 BC, when 
it was believed that spinal cord injuries should not be 
treated. This description was made by Edwin Smith 
apud Barros Filho(3).
During the First World War, 80% of the patients 
with spinal cord trauma died within the first two weeks 
after the trauma(3).
During the Second World War, the concept of 
specialized spinal cord injury centers was developed 
in England. At these centers, with multidisciplina-
ry teams, it was possible to dramatically reduce the
mortality rate(3).
Spinal cord trauma used to be regarded as an un-
treatable disease. Until ten years ago, all that could 
be done was to stabilize the spine, treat infections and 
361
ADVANCES IN THE USE OF STEM CELLS IN ORTHOPEDICS
potential for functional recovery among such patients. 
These drugs aim to interrupt the physiopathological 
mechanisms of secondary neuronal lesions(31-34) (Fi-
gures 3 and 4).
The ideal treatment for spinal cord injuries would 
be one that not only diminished the lesion but also 
stimulated the repair process. Contrary to the con-
cepts of ten years ago, it has now been proven that 
neurons outside of the central nervous system, in the 
immature spinal cord and in special culture media 
may regenerate(58).
Lines of research involving neurotransmitter use, 
fetal cell transplantation, undifferentiated cell trans-
plantation, electrode implantation and use of remye-
lination-promoting substances have now been develo-
ped, but they have not yet presented definitive results.
Over the last ten years, use of stem cells in treat-
ments for spinal cord injuries has been described in 
several experimental studies, with beneficial effects. 
The way in which these cells may act in repairing 
lesions of the nervous system is still a matter of con-
troversy, but it certainly involves phenomena like 
functional reconstruction of neuronal circuits, with 
reestablishment of synapses or interconnections with 
host cells; production of neurochemical substances 
like neurotransmitters, growth factors and antibo-
dies; and remyelination of undamaged axons that 
stopped producing electrical impulses because they
were demyelinated.
Thus, at the Institute of Orthopedics and Trauma-
tology, Hospital das Clínicas, School of Medicine of 
the University of São Paulo, a clinical trial was con-
ducted to assess the effect of infusion of autogenous 
undifferentiated progenitor cells for treating patients 
with chronic spinal cord lesions(59).
Thirty-nine patients who had presented trauma-
tic spinal cord injury with a complete deficit for at
least two years were selected. All of them followed a 
protocol to obtain their informed consent. The follo-
wing were then performed: hemogram, coagulogram, 
magnetic resonance imaging on the spine and soma-
tosensory evoked potential. None of the 39 patients 
presented any registered transmission of impulses to 
the cerebral cortex after stimulation of the lower limbs.
To obtain progenitor cells from the patients’ pe-
ripheral blood, they were administered G-CSF. Five 
days later, stem cells were collected from the patients 
by means of an apheresis technique, using a conti-
nuous-flow cell separator. Through this, we obtained 
2.5 x 106 CD34+ cells per kilogram of patient weight, 
which were cryopreserved. Following this, these cells 
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Figure 3 – Primary injury.
Figure 4 – Result after secondary lesion.
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Clinical and scientific advances have indicated that 
acute lesions in the spinal cord can be manipulated 
by means of pharmacological therapy if used within 
a short space of time. Methylprednisolone adminis-
tered within the first eight hours after the trauma was 
the first agent to produce a significant improvement 
in the recovery from spinal cord trauma in human
beings(4,35-46). Other drugs, like tirilazad(47-49) and
GM-1(50-57) have presented promising preliminary 
results. These advances may provide a great impro-
vement in the quality of life of patients with spinal 
cord injuries, if they are brought into clinical practi-
ce. After injuries to the central nervous system, there 
is a period of deficit followed by a period of varying 
degrees of functional recovery. This recovery is due 
mainly to changes to the uninjured circuits, but the 
exact process involved in the recovery remains in-
completely understood. 
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were cultured in a medium appropriate for developing 
cells of neuronal lineage. 
These cells were infused by means of arterial an-
giography, which irrigated the lesion site and perfused 
the anterior spinal artery. We used dimethyl sulfoxide 
as the vehicle (Figure 5).
Despite this response, the patients did not achieve 
any motor gains, clinically. Some showed nonspecific 
sensory improvement in the lower limbs. The compli-
cations observed  with this therapeutic method inclu-
ded one case of pneumothorax consequent to passage 
of the double-lumen catheter to collect stem cells, and 
three cases of allergy to the contrast medium used in 
the arteriography(59).
CARTILAGINOUS TISSUE
The primordial cells have also been studied in re-
lation to formation of joint cartilage. Diseases like 
traumatic chondral lesions, osteochondritis dissecans, 
patellar chondromalacia and osteoarthrosis are thera-
peutic targets for these cells(58).
When traumatic chondral lesions of the ankle and 
knee are small and in areas of low mechanical stress, 
they are usually treated conservatively, including res-
trictions on bearing the body weight, use of analge-
sics and anti-inflammatory drugs, and physiotherapy 
(Figure 8). When these lesions are extensive, they 
can be treated by means of perforation, autologous 
or homologous osteochondral grafts, replacement ar-
throplasty (partial or total prostheses) and arthrodesis.
Osteochondritis dissecans of the knee is a common 
disorder of unknown cause. It is thought that it may 
result from ischemia in a certain localized area of 
subchondral bone that is precipitated by infarction, 
trauma or other causes. The treatment for osteochon-
dritis dissecans of the knee in children is conservati-
ve because the fragments are unstable. In adults too, 
the fragments are unstable, but can be excised when 
small and outside of the load-bearing area. When the 
fragments are bigger and in load-bearing areas, they 
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Figure 5 – Spinal cord angiography at the lesion site, showing 
perfusion of the anterior spine.
The patients were then followed up clinically, 
by means of somatosensory evoked potential and 
urodynamics.
The final result was that transmission of impulses 
in the cerebral cortex or improvement in the latency 
time for obtaining a cortical response after stimula-
tion of the upper and lower limbs was registered in 
26 patients. However, the sensory conduction took 
longer, with greater latency than in normal individuals 
(Figures 6 and 7).
Figure 6 –  Pre-infusion somatosensory evoked potential.
Figura 7 – Post-infusion somatosensory evoked potential.
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should be treated by means of perforation or curetta-
ge in association with fixation of the fragment, and 
also by means of homologous osteochondral grafts or 
arthroplasty (Figures 9 and 10).
In cases of patellar chondromalacia, the treatment 
depends on the degree of injury. If the lesion is less 
extensive and shallower, it can be treated conservati-
vely. If it is deep, often with exposure of subchondral 
bone, it can be treated by means of curettage, perfora-
tion and autologous grafting. The surgical results are 
worse than when the femur or tibia is affected.
In cases of hip and knee osteoarthrosis, both con-
servative and surgical treatment options exist (Figu-
res 11 and 12). The current arsenal of conservative 
treatment methods includes chondroprotective agents 
(hyaluronic acid, glucosamine and chondroitin),
which have presented satisfactory results in all stu-
dies on humans, albeit with short follow-up duration. 
When conservative treatment fails, osteotomy, repla-
cement arthroplasty or arthrodesis can be indicated. 
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Figure 8 – Osteochondral lesion of the talus.
Figures 9 and 10 – AP and lateral radiographs on a patient with 
osteochondritis dissecans of the medial femoral condyle in a load-
bearing area.
Figures 11 and 12  - Osteoarthrosis in the right knee and left hip.
Autologous and heterologous grafts have greater fai-
lure rates than seen in other joint cartilage diseases.
The importance of stem cells as a new method for 
treating chondral lesions is due to the fact that joint 
cartilage has little capacity for repair. The technique 
of transplanting cultures of autologous chondrocytes 
into chondral defects is restricted to small lesions 
in young individuals. On the other hand, recent stu-
dies have proven that mesenchymal progenitor cells 
may be able to repair larger defects, independent 
of age. The major problems are still the culturing, 
induction of differentiation and adherence at the
lesion site(59-61).
In addition to stem cells, growth factors are needed 
in order to determine the proliferation and differen-
tiation in cartilaginous tissue, both during in vitro 
culturing and at the time of implantation. One of these 
factors is prolactin, which induces cell proliferation, 
proteoglycan synthesis and cell interaction, and inhi-
bits the formation of type II collagen. Other factors 
that determine chondrogenesis include the insulin-like 
growth factor 1 (IGF-1) and the transformer growth 
factor beta 1 (TGFb1)(62,63).
With this new therapeutic technique, the morbi-
dity in the donor area can be diminished in cases of 
mosaic grafting (removal of small mosaics of carti-
lage from an area of lower loading to another with 
an osteochondral defect); the passage of pathogens 
and deterioration of allografts can be avoided; and 
revisions due to loosening or worm material in cases 
of joint prostheses can be avoided(64).
Greater-impact studies on humans are needed in 
order to define the real purpose of stem cells in joint 
cartilaginous diseases.
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BONE TISSUE
In traumatology, one of the major complications is 
the condition of so-called pseudarthrosis. This word 
means false articulation and is used to denote nonu-
nion of the fragments of a mild fracture that leads 
to formation of a pseudocapsule with synovium and 
synovial fluid.
Pseudarthrosis can be divided into two main types: 
hypertrophic or hypervascular and atrophic or avas-
cular. The main cause of the first type is movement 
at the fracture focus and main cause of the second 
type is a lack of local biological conditions for bone 
consolidation (Figure 13).
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Figure 13 – Hypertrophic pseudarthrosis of bones of the right 
leg and atrophic pseudarthrosis of the left leg.
In hypertrophic pseudarthrosis, the treatment aims 
to improve the stability of the fracture, through plaster 
casts, orthoses, osteosynthesis or external fixators. 
The advantage of these last two is that as well as 
stabilizing the fracture, they can compress the focus.
Stem cells are applicable as a form of treatment 
in relation to the second type of pseudarthrosis, i.e. 
the atrophic type (Figures 13 and 14). Consolidation 
is known to consist of three phases: I-inflammation, 
in which infiltration of leukocytes occurs and causes 
chemotaxis of mesenchymal cells and fibroblasts, 
which become differentiated into osteoblasts; II-repair, 
in which a soft callus is formed (flaccid fibroblastic 
connective tissue) and then a hard callus (immature 
bone tissue); and III-remodeling, in which the mature 
Figure 14 – Avascular pseudarthrosis of the femoral diaphysis.
bone tissue is formed. Thus, progenitor cells could 
have an influence in the first two phases(64).
Physical methods such as ultrasound and electro-
magnetic pulses can be used as treatment variations 
for atrophic pseudarthrosis, although the results are 
doubtful. Studies with a higher level of evidence 
(randomized controlled clinical trials) with a lon-
ger follow-up are needed in order to reach definitive
conclusions. 
Autologous grafts (from the iliac, tibia or distal ra-
dius) or homologous grafts (bone from a tissue bank) 
can also be used. The great advantage of autologous 
grafts is their osteogenic, osteoconductive and os-
teoinductive capacity. Osteogenesis occurs because of 
the microenvironment that is formed with trophic fac-
tors. These cause recruitment of mesenchymal cells 
and fibroblasts, and their differentiation into bone tis-
sue. Osteoinduction relates to specific proteins that 
cause local bone growth. Osteoconduction relates to 
the substrate or framework within which bone can be 
formed. Grafts from a bank and bone substitutes like 
hydroxyapatite only have osteoconductive capacity.
Bone morphogenetic protein (BMP) is another 
form of treatment for atrophic pseudarthrosis, with 
osteoinductive capacity.
One simple technique for local infiltration of toti-
potent cells is to use an aspirate from the bone mar-
row of the iliac. However, the low cellularity of this 
material makes the method questionable. Its action is 
perhaps due more to the presence of BMP than to the 
presence of totipotent cells(65).
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For stem cell therapy to be successful, high cellulari-
ty in the collected material is needed, with adequate cul-
turing to form bone lineage cells and trophic factors(63).
Use of stem cells to form bone tissue gives rise 
to diminished morbidity in the bone graft donor area 
and avoids disease transmission through homologous 
grafts(64,65).
There are very few studies on stem cells used for 
bone formation. An experimental study on rats sho-
wed that there was a benefit from using stem cells at 
osteotomy foci that were under treatment with rela-
xation using external fixators, thereby giving rise to 
improved local vascularization and faster consolida-
tion, within one to two weeks(66).
DENSE CONNECTIVE TISSUE
Ligaments and tendons are formed by true connec-
tive tissue of dense type. For this to occur, traction 
forces are needed. This tissue is mainly composed of 
fibroblasts and types I and III collagen fibers.
The anterior cruciate ligament (ACL) and medi-
cal collateral ligament (MCL) of the knee are the 
structures that are most often injured in sports prac-
tice, accounting for up to 90% of injured ligaments. 
The MCL is treated conservatively, but the ACL is 
preferentially treated by means of arthroscopic re-
constructive surgery. Today, the options available for 
autologous grafting for the ACL consist mainly of 
the patellar, semitendinosus, gracilis and quadriceps 
tendons. Homologous grafts from the Achilles tendon 
form an alternative. The greatest criticism of these 
surgical procedures is the morbidity in the donor area. 
In such cases, stem cells would avoid this nuisance(64).
There are studies demonstrating different degrees of 
regeneration of intra-articular tissue in affected knees, 
including ACL, meniscal or chondral lesions, after in-
jections of stem cells into the joint. This provides a new 
therapeutic option for these joint lesions(67) (Figure 15).
 The Achilles tendon is one of the tendons most 
subjected to injury. The treatment can be conserva-
tive or surgical. The advantage of conservative tre-
atment is that it avoids surgical complications like 
skin necrosis, infection or neurovascular lesions. The 
disadvantage is the lower resistance and consequently 
greater risk of renewed tearing. The inverse applies 
to surgical treatment. The surgical options consist of 
open repair using a Krackow suture, percutaneous 
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repair using an “x” suture and various types of tendon 
reinforcement (long flexor of the hallux, short plan-
tar ligament, short fibular ligament and aponeurosis 
of the sural triceps). Stem cells have become a new 
technique that in the future may be applied to cases 
of tendon failure without increasing the duration of 
surgery and without loss of function of the transferred 
tendons (Figure 16 ).
Figure 16 – Intraoperative photo after resection of the torn diseased 
tendon, with reinforcement using the long flexor tendon of the hallux.
Figure 15 – Lesion of the medial meniscus.
FINAL REMARKS
There are many studies on the topic of stem cells in 
the literature, both in the form of experimental studies 
and in the form of clinical trials. This topic appears to 
be one of the most promising fields within medicine, 
capable of providing solutions for diseases that so far 
have not had any solutions.
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